• +1-646-491-9876
    • +91-20-67278686

    Search

    Glucose Dependent Insulinotropic Receptor-Pipeline Review H2 2017

    Glucose Dependent Insulinotropic Receptor-Pipeline Review H2 2017

    • Report Code ID: RW00011199526
    • Category Life Sciences
    • No. of Pages 50
    • Publication Month Oct-17
    • Publisher Name Global Markets Direct
    Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119)-Pipeline Review, H2 2017

    Summary

    According to the recently published report 'Glucose Dependent Insulinotropic Receptor-Pipeline Review, H2 2017'; Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) pipeline Target constitutes close to 17 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes.

    Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119)-G protein-coupled receptor 119 also known as GPR119 is a G protein-coupled receptor that is encoded by the GPR119 gene. GPR119 is expressed at high concentrations in the pancreas and gastrointestinal tract. GPR119 regulates incretin and insulin hormone secretion. Activation of GPR119 receptor causes a reduction in food intake and weight gain. This target is a potential drug target in treatments for obesity and diabetes.

    The report 'Glucose Dependent Insulinotropic Receptor-Pipeline Review, H2 2017' outlays comprehensive information on the Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

    It also reviews key players involved in Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 12 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Respiratory and Undisclosed which include indications Type 2 Diabetes, Obesity, Chronic Obstructive Pulmonary Disease (COPD), Dyslipidemia and Unspecified.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    -The report provides a snapshot of the global therapeutic landscape for Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119)
    -The report reviews Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    -The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    -The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    -The report reviews key players involved in Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics and enlists all their major and minor projects
    -The report assesses Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
    -The report summarizes all the dormant and discontinued pipeline projects
    -The report reviews latest news and deals related to Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics

    Reasons to buy

    -Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    -Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    -Identify and understand the targeted therapy areas and indications for Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119)
    -Identify the use of drugs for target identification and drug repurposing
    -Identify potential new clients or partners in the target demographic
    -Develop strategic initiatives by understanding the focus areas of leading companies
    -Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    -Devise corrective measures for pipeline projects by understanding Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) development landscape
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119)-Overview
    Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119)-Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119)-Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119)-Companies Involved in Therapeutics Development
    Amgen Inc
    Arena Pharmaceuticals Inc
    CymaBay Therapeutics Inc
    Dong-A Socio Holdings Co Ltd
    F. Hoffmann-La Roche Ltd
    GlaxoSmithKline Plc
    Hyundai Pharmaceutical Co Ltd
    Kowa Co Ltd
    Merck & Co Inc
    Novartis AG
    Taisho Pharmaceutical Holdings Co Ltd
    Takeda Pharmaceutical Co Ltd
    Yuhan Corp
    Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119)-Drug Profiles
    DA-1241-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GSK-2041706-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HD-0471042-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HD-0471953-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HOB-047-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MBX-2982-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SCO-094-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Agonize GPR119 for Type 2 Diabetes-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Agonize GPR119 for Type 2 Diabetes-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Agonize GPR119 for Type II Diabetes-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Agonize GPR119 Receptor for Unspecified Indication-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Agonize GRP119 for Type 2 Diabetes and Obesity-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Agonize GPR119 for Type 2 Diabetes-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Agonize GPR119 for Type 2 Diabetes-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Agonize GPR119 for Type 2 Diabetes-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Agonize GPR119 Receptor for Type 2 Diabetes-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    YH-18420-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119)-Dormant Products
    Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119)-Discontinued Products
    Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119)-Product Development Milestones
    Featured News & Press Releases
    Nov 05, 2009: Metabolex Closes $8.6 Million Financing Round
    Nov 12, 2008: Metabolex Announces Positive Results From Phase 1a Clinical Trial Of MBX-2982
    Mar 26, 2008: Metabolex, Inc. Initiates Phase 1 Trial Of MBX-2982
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables
    Number of Products under Development by Stage of Development, H2 2017
    Number of Products under Development by Therapy Areas, H2 2017
    Number of Products under Development by Indication, H2 2017
    Number of Products under Development by Companies, H2 2017
    Products under Development by Companies, H2 2017
    Number of Products under Investigation by Universities/Institutes, H2 2017
    Products under Investigation by Universities/Institutes, H2 2017
    Number of Products by Stage and Mechanism of Actions, H2 2017
    Number of Products by Stage and Route of Administration, H2 2017
    Number of Products by Stage and Molecule Type, H2 2017
    Pipeline by Amgen Inc, H2 2017
    Pipeline by Arena Pharmaceuticals Inc, H2 2017
    Pipeline by CymaBay Therapeutics Inc, H2 2017
    Pipeline by Dong-A Socio Holdings Co Ltd, H2 2017
    Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
    Pipeline by GlaxoSmithKline Plc, H2 2017
    Pipeline by Hyundai Pharmaceutical Co Ltd, H2 2017
    Pipeline by Kowa Co Ltd, H2 2017
    Pipeline by Merck & Co Inc, H2 2017
    Pipeline by Novartis AG, H2 2017
    Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H2 2017
    Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017
    Pipeline by Yuhan Corp, H2 2017
    Dormant Products, H2 2017
    Dormant Products, H2 2017 (Contd..1), H2 2017
    Discontinued Products, H2 2017

    List of Figures
    Number of Products under Development by Stage of Development, H2 2017
    Number of Products under Development by Therapy Areas, H2 2017
    Number of Products under Development by Indications, H2 2017
    Number of Products by Stage and Mechanism of Actions, H2 2017
    Number of Products by Routes of Administration, H2 2017
    Number of Products by Stage and Routes of Administration, H2 2017
    Number of Products by Stage and Molecule Type, H2 2017
    Amgen Inc
    Arena Pharmaceuticals Inc
    CymaBay Therapeutics Inc
    Dong-A Socio Holdings Co Ltd
    F. Hoffmann-La Roche Ltd
    GlaxoSmithKline Plc
    Hyundai Pharmaceutical Co Ltd
    Kowa Co Ltd
    Merck & Co Inc
    Novartis AG
    Taisho Pharmaceutical Holdings Co Ltd
    Takeda Pharmaceutical Co Ltd
    Yuhan Corp

    Request for Sample

    Report Url http://www.reportsweb.com//glucose-dependent-insulinotropic-receptor-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//glucose-dependent-insulinotropic-receptor-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//glucose-dependent-insulinotropic-receptor-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments